Ulcerative Colitis (M14-533)

M14-533 is an extension study of M14-234.

The purpose of this study is to evaluate the long-term safety and efficacy of ABT-494 in subjects with Ulcerative Colitis (UC) who have not responded at the end of the induction period in Study M14-234, who have been inadequate responders during the maintenance period of Study M14-234, or who have responded and successfully completed Study M14- 234. The long-term safety data collected will be used to better assess the risk to benefit profile of ABT-494 in subjects with UC.

ABT-494 is an experimental drug that blocks the actions of proteins known as Janus kinases (Jaks). Jaks are involved in the immune response and the production of blood cells and other proteins. ABT-494 is being studied in subjects with rheumatoid arthritis, inflammatory bowel disease and other inflammatory diseases.


Register Today!

Trial Information

Start DateDecember 2016
End DateTBD
Trial Duration288 weeks
Number of Visits27

For additional information
on this trial contact: